Cyclophosphamide, Etoposide and Cisplatin IV Infusion
Formulary
Cytarabine Intrathecal Injection
Formulary
Cytarabine IV Infusion
Formulary
Cytarabine IV Injection
Formulary
Cytarabine SC Injection
Formulary
Dacarbazine IV Infusion
Formulary
Daratumumab IV Infusion
Formulary
Daunorubicin IV Infusion
Formulary
Daunorubicin liposomal IV Infusion
Formulary
Doxorubicin IV Infusion
Formulary
Doxorubicin IV Injection
Formulary
Epirubicin IV Injection
Formulary
Etoposide IV Infusion
Formulary
Etoposide, Doxorubicin and Vincristine IV Infusion
Formulary
Fludarabine IV Infusion
Formulary
Fluorouracil Ophthalmic
Formulary
Foscarnet IV Infusion
Formulary
Ganciclovir IV Infusion (Adult bag)
Formulary
Ganciclovir IV Infusion (Paediatric syringe)
Formulary
Gemcitabine IV Infusion
Formulary
Gemtuzumab IV Infusion
Formulary
Idarubicin IV Infusion
Formulary
Ifosfamide and Mesna IV Infusion
Formulary
Infliximab IV Infusion (Inflectra)
Formulary
Infliximab IV Infusion (Remicade)
Formulary
Infliximab IV Infusion (Remsima)
Formulary
Outsourced product - not prepared by PAT Aseptic Services
Methotrexate IM Injection
Formulary
Methotrexate Intrathecal Injection
Formulary
Methotrexate IV Infusion
Formulary
Mitoxantrone IV Infusion
Formulary
Mytomycin Ophthalmic
Formulary
Obinutuzumab IV Infusion
Formulary
Ofatumumab IV Infusion
Formulary
Pentostatin IV Infusion
Formulary
Pixantrone IV Infusion
Formulary
Rituximab IV Infusion
Formulary
Rituximab SC Injection
Formulary
Savene IV Infusion (Dexrazoxane)
Formulary
Thiotepa IV Infusion
Formulary
Tocilizumab IV Infusion
Formulary
Vedolizumab IV Infusion
Formulary
Vinblastine IV Infusion
Formulary
Vincristine IV Infusion
Formulary
....
Key
Notes
Section Title (top level)
Section Title (sub level)
First Choice item
Non Formulary section
Restricted Drug
Unlicensed
Display tracking information
Link to adult BNF
Link to children's BNF
Link to SPCs
Scottish Medicines Consortium
Cytotoxic Drug
Controlled Drug
High Cost Medicine
Cancer Drugs Fund
NHS England
Homecare
CCG
Traffic Light Status Information
Status
Description
Drugs designated amber are suitable for shared care arrangements under a shared care protocol.
Prescribing may be transferred from secondary to primary care once the patient is stabilised and agreed shared care arrangements have been established. Alternatively primary care may initiate under the supervision of secondary care if this option is given in the shared care document. It is recommended that shared care arrangements should be drawn up following local discussion and agreement by prescribing parties.
These products have been reviewed by the GM Joint Formulary Group and have been deemed not suitable for prescribing for adults in primary or secondary care within Greater Manchester. These decisions have been made on the basis of safety, efficacy and cost-effectiveness of the products.
Not used
Drugs designated green1 are suitable for initiation and ongoing prescribing within primary care.
Drugs designated green2 can be initiated by primary care following written or verbal advice from a specialist and then be subsequently safely prescribed in primary care with little or no monitoring required.
Drugs designated green3 are suitable for on-going prescribing within primary care after specialist initiation and an initial review (unless specified) in secondary care. Little or no monitoring is required.
Not suitable for routine prescribing but may be suitable for a defined patient population. Whilst prescribers should think very carefully before prescribing or recommending any of the products on the grey list, there may be exceptional instances when the use of one of these products is necessary for a particular patient.
Drugs designated red are considered to be specialist medicines and prescribing responsibility for these medicines should normally remain with the consultant or specialist clinician. These drugs should not be initiated or prescribed in primary care. It is recommended that the supply of these specialist medicines should be organised via the hospital pharmacy, this may include arranging for supply via a home care company.
